Skip to main content

Research-informed explainer · Last reviewed April 11, 2026

Migraine vs. Ocular Flare: How to Tell the Difference

Eye pain, light sensitivity, and blurred vision can mean a migraine or an ocular flare. Here is how to tell them apart and when each needs urgent care.

Migraine and an ocular flare both cause light sensitivity, and both can blur your vision — but they are two different problems with very different consequences if you wait too long. A migraine is a neurological event driven by the brain. An ocular flare is active inflammation inside the eye itself, usually uveitis, or sometimes a worsening of dry eye disease. Getting the two confused can mean treating the wrong thing, which for uveitis can lead to permanent vision loss.

This explainer draws on published research from five ophthalmology specialists in the Convene directory. Eric Suhler, MD, at Oregon Health and Science University has co-authored foundational studies on how common noninfectious uveitis is and how it behaves over time [1][2][5]. Careen Lowder, MD, at Cleveland Clinic has published extensively on uveitis treatment including the landmark dexamethasone implant trial [4] and the clinical profile of HLA-B27 uveitis [3]. Shree Kurup, MD, at University Hospitals Cleveland co-authored the VISUAL II trial defining what a uveitic flare looks like clinically [6]. Ashley Crane, MD, in Tampa has studied how central sensitization produces eye pain that mimics migraine [7]. Nandini Venkateswaran, MD, at Massachusetts General Hospital has published on photophobia in non-migraine patients [8].

What is a uveitis flare?

Uveitis is inflammation of the uvea, the middle layer of the eye that includes the iris, ciliary body, and choroid. A flare means the inflammation has returned or worsened after a period of control. The VISUAL II trial [6], which enrolled patients with uveitis that had been controlled on corticosteroids, defined a flare as either new active inflammation in the anterior chamber or vitreous, or a worsening of known inflammation requiring treatment escalation.

Uveitis is not rare. Research by Suhler and colleagues found a prevalence of roughly 121 cases per 100,000 adults in the United States [1]. An earlier study by the same group found similar rates in the VA Pacific Northwest population [2]. Many cases are linked to systemic immune conditions: HLA-B27-associated disorders (ankylosing spondylitis, reactive arthritis, psoriatic arthritis), sarcoidosis, and juvenile idiopathic arthritis. Research by Lowder and colleagues published in the American Journal of Ophthalmology identified that HLA-B27-positive patients typically present with acute anterior uveitis: sudden-onset pain, redness, and photophobia, often in one eye, with a pattern of recurrent flares [3].

What is a migraine?

Migraine is a neurological disorder. The pain is generated in the brain, not the eye, even though it can feel like it is behind one eye. Classic migraine comes with a unilateral throbbing headache, nausea, and strong sensitivity to light and sound. Migraine with aura adds a visual phase before the headache: typically shimmering zigzag lines (a scintillating scotoma) or a crescent of blind spot that grows over 20 to 30 minutes and then fades, usually followed by headache.

The visual aura of migraine is bilateral. Both visual fields are affected even if the distortion seems to be on one side. It is self-limited and clears completely within an hour. The eye itself is structurally unaffected.

How to tell them apart

The single most useful question to ask yourself: where exactly is the pain?

Uveitis causes pain in or around the eye. Patients often describe a deep, dull ache that worsens with light, sometimes radiating to the brow or temple. In anterior uveitis, the eye becomes red with a characteristic ring of redness at the limbus (the edge where the iris meets the white of the eye), called ciliary flush. The pupil may be irregular or constricted. Floaters (dark spots or threads that drift across your vision) are common, especially in intermediate or posterior uveitis.

Migraine headache is typically in the head: temple, forehead, back of the skull. The eye itself does not ache. The visual symptoms of migraine aura move, evolve, and resolve within minutes to an hour. Floaters are not a typical migraine symptom. The eye is not red.

At a glance

FeatureMigraineOcular (uveitis) flare
Where the pain isHead, temple, foreheadIn or around the eye itself
Eye rednessNoYes, especially at the limbus (ciliary flush)
Visual disturbanceMoving zigzag lines, scotoma — resolves within an hourBlurred vision, floaters — persists
FloatersRareCommon (intermediate or posterior uveitis)
NauseaCommonUncommon
HeadacheYesMild brow ache possible, but not the primary symptom
DurationHoursDays to weeks without treatment
Both eyesAura affects both visual fieldsUsually one eye at a time
PhotophobiaYesYes
Urgent?Usually not — unless first severe attackYes — see an ophthalmologist the same day

Why light sensitivity is not a reliable separator

Both conditions cause photophobia, which is why so many patients get confused. In migraine, photophobia is driven by neural pathways in the brain. In uveitis, it happens because the inflamed iris is hypersensitive to light-triggered pupil constriction, which mechanically hurts.

There is a third possibility worth knowing: photophobia in the absence of migraine or uveitis. Research by Venkateswaran and colleagues documented patients with severe photophobia and dryness who did not have migraine, and whose symptoms responded to periorbital botulinum toxin, pointing to a peripheral rather than central origin for their light sensitivity [8]. Similarly, research by Crane and colleagues found evidence of central sensitization in patients with persistent ocular pain after topical anesthesia, meaning the pain pathways in the brain can amplify ocular surface signals [7]. This matters because it shows that overlapping pain mechanisms can make the two conditions harder to separate on symptoms alone.

The role of floaters in telling the two apart

Floaters are one of the more reliable distinguishing features. They are not a migraine symptom. If you are seeing new floaters along with light sensitivity and blurred vision, that combination is more consistent with uveitis: intermediate uveitis (inflammation of the vitreous) or posterior uveitis (inflammation of the retina or choroid).

New floaters with photopsia (flashing lights) can also signal a posterior vitreous detachment or retinal tear, which is a separate urgency. Any sudden new floaters, especially with flashing lights, warrant a same-day call to an ophthalmologist.

When each condition typically needs treatment

Migraine management ranges from over-the-counter analgesics and triptans for acute attacks, to preventive medications (beta-blockers, CGRP inhibitors, topiramate) for frequent migraine. Most attacks resolve without any permanent eye or vision consequences.

Uveitis is different. Untreated inflammation can cause glaucoma, cataracts, macular edema, and permanent vision loss. The standard first-line treatment for a flare is corticosteroid eye drops or, for more posterior disease, corticosteroid injections. For patients with recurrent or chronic uveitis, longer-acting approaches are used: Lowder and colleagues published a trial showing that a slow-release dexamethasone intravitreal implant (Ozurdex) reduces flare risk compared to sham injection in patients with intermediate or posterior uveitis [4]. For patients whose uveitis is driven by systemic immune disease, biologic therapies targeting TNF-alpha have changed management significantly. The VISUAL I trial (with Suhler as a lead investigator) showed that adalimumab reduced the risk of uveitic flare and vision impairment in patients with active noninfectious uveitis [5]. The VISUAL II trial [6], which enrolled patients in remission, showed adalimumab also prevented new flares compared to placebo.

For juvenile idiopathic arthritis-related uveitis, the evidence is more nuanced. A randomized trial by Suhler and colleagues found that etanercept (another TNF inhibitor) did not reduce anterior segment inflammation compared to placebo in this pediatric population, which is one reason adalimumab became the preferred biologic for JIA-associated uveitis rather than etanercept [9].

Questions to ask your doctor

  • Is my photophobia coming from my eye surface, my eye's interior, or my brain? How do you tell?
  • If I have had a confirmed migraine diagnosis, should I still see an ophthalmologist to rule out uveitis if I get a new episode of eye pain and redness?
  • I have an autoimmune condition (ankylosing spondylitis, psoriasis, IBD, sarcoidosis). Does that change my risk for uveitis flares?
  • If I am having recurring episodes of red, painful eyes with light sensitivity, what tests can confirm uveitis?
  • How often do uveitis flares come back, and what can reduce the frequency?

The bottom line

Migraine pain lives in the head. Ocular flare pain lives in the eye. That distinction, combined with whether your eye is red and whether you have floaters, gets you most of the way to knowing which one you are dealing with. Both cause photophobia, so that symptom alone does not separate them. If your eye is visibly red, if you have floaters, or if your light sensitivity and blurred vision are not clearing within an hour, you are more likely looking at an ocular flare than a migraine, and that requires a same-day ophthalmology visit, not a dark room and ibuprofen.

Research informing this article

Peer-reviewed research from the following specialists listed on Convene informs this explainer. They did not write or review the article; their published work is cited throughout.

Sources

  1. 1.
    Prevalence of Noninfectious Uveitis in the United StatesJAMA Ophthalmology, 2016. DOI
  2. 2.
    Incidence and Prevalence of Uveitis in Veterans Affairs Medical Centers of the Pacific NorthwestAmerican Journal of Ophthalmology, 2008. DOI
  3. 3.
    Clinical Features and Associated Systemic Diseases of HLA-B27 UveitisAmerican Journal of Ophthalmology, 1996. DOI
  4. 4.
    Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior UveitisArchives of Ophthalmology, 2011. DOI
  5. 5.
    Adalimumab in Patients with Active Noninfectious UveitisNew England Journal of Medicine, 2016. DOI
  6. 6.
    Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trialThe Lancet, 2016. DOI
  7. 7.
    Evidence of central sensitisation in those with dry eye symptoms and neuropathic-like ocular pain complaints: incomplete response to topical anaesthesia and generalised heightened sensitivity to evoked painBritish Journal of Ophthalmology, 2017. DOI
  8. 8.
    Periorbital botulinum toxin A improves photophobia and sensations of dryness in patients without migraine: Case series of four patientsAmerican Journal of Ophthalmology Case Reports, 2020. DOI
  9. 9.
    A randomized, placebo‐controlled, double‐masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritisArthritis Care & Research, 2005. DOI
  10. 10.
    Low-dose Methotrexate Therapy for Ocular Inflammatory DiseaseOphthalmology, 1992. DOI

Related articles